Table 1.

Fifteen randomized, placebo-controlled trials assessing the effect of statins on renal outcomes in diabetic nephropathy

Studies	Country	Intervention	Sample sizes (n)		Use of ACEI or ARB (%)		Mean age (years)		Duration of diabetic nephropathy, (years)		Follow-up (months)
			statin	control	statin	control	statin	control	statin	control
CARDS 2009 [9]	UK	Atorvastatin, 10 mg/d	1154	1159	44.6	43.6	61.5	61.8	—	—	24
Masanori 2011 [10]	Japan	Rosuvastatin, 2.5–10 mg/d	52	52	100	100	64.5	64.9	—	—	6
Dalla 2003 [11]	Italy	Atorvastatin 10 mg/d	12	13	0	0	66	63	10	9	12
Linda 2001 [12]	USA	Simvastatin, 10 mg/d	19	20	5	15	33.3	31.0	22.8	20.8	18
E. Hommel 1992 [13]	Denmark	Simvastatin, 10–20 mg/d	12	9	67	89	41	35	27	27	3
Lam 1995 [14]	China	Lovastatin, 30 mg/d	16	18	12.5	16.7	58.9	53.9	—	—	24
S.Nielsen 1993 [15]	Denmark	Simvastatin 10–20 mg/d	8	10	0	0	65	65	10.2	10.9	9
Zhang 1995 [16]	Belgium	Pravastatin, 20 mg	10	10	—	—	43	43	—	—	3
Giancarlo 1997 [17]	Italy	Simvastatin, 20 mg/d	10	9	0	0	60	62	—	—	12
Tsukasa 2005 [18]	Japan	Pitavastatin, 1 mg/d	10	10	—	—	51	49	13	12	12
Tsukasa 2001 [19]	Japan	Cerivastatin, 0.15 mg/d	30	30	—	—	58	55	—	—	6
Wu 2013 [20]	China	Atorvastatin, 20 mg/d	39	39	100	100	55.15	55.33	5.18	4.82	6
Du 2015 [21]	China	Atorvastatin, 20 mg/d	26	26	100	100	56	57	10	10	3
Xiang 2005 [22]	China	Simvastatin, 20 mg/d	32	31	100	100	50	49	15	14	6

USA the United States of America, UK United Kingdom, T2DM type 2 diabetes mellitus, T1DM type 1 diabetes mellitus, —:not report